» Articles » PMID: 39494754

Personalized CZA-ATM Dosing Against an XDR E. Coli in Liver Transplant Patients; the Application of the in Vitro Hollow Fiber System

Overview
Date 2024 Nov 4
PMID 39494754
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A patient with an extensively drug-resistant (XDR) New Delhi metallo-β-lactamase (NDM) and oxacillinase (OXA-48) producing Escherichia coli (E. coli) infection was awaiting orthotopic liver transplant. There is no standardized antibiotic prophylaxis regimen; however, in line with the Infectious Diseases Society of America guidance, an antibiotic prophylactic regimen of ceftazidime-avibactam 2.5 g TDS with aztreonam 2 g three times a day (TDS) IV was proposed.

Methods: The hollow fiber system (HFS) was applied to inform the individualized pharmacodynamic outcome likelihood prior to prophylaxis.

Results: A 4-log reduction in CFU/mL in the first 10 h of the regimen exposure was observed; however, the killing dynamics were slow and six 8-hourly infusions were required to reduce bacterial cells to below the limit of quantification. Thus, the HFS supported the use of the regimen for infection clearance; however, it highlighted the need for several infusions. Standard local practice is to administer prophylaxis antibiotics at induction of orthotopic liver transplantation (OLT); however, the HFS provided data to rationalize earlier dosing. Therefore, the patient was dosed at 24 h prior to their OLT induction and subsequently discharged 8 days after surgery.

Conclusion: The HFS provides a dynamic culture solution for informing individualized medicine by testing antibiotic combinations and exposures against the bacterial isolates cultured from the patient's infection. .

Citing Articles

Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fiber system.

Sadouki Z, Wey E, Iype S, Nasralla D, Potts J, Spiro M Transpl Infect Dis. 2024; 27(1):e14396.

PMID: 39494754 PMC: 11827718. DOI: 10.1111/tid.14396.

References
1.
Abbo L, Grossi P . Surgical site infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9):e13589. DOI: 10.1111/ctr.13589. View

2.
Yasmin M, Fouts D, Jacobs M, Haydar H, Marshall S, White R . Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. Clin Infect Dis. 2019; 71(4):1095-1098. PMC: 7428388. DOI: 10.1093/cid/ciz1155. View

3.
Gajic I, Kabic J, Kekic D, Jovicevic M, Milenkovic M, Culafic D . Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods. Antibiotics (Basel). 2022; 11(4). PMC: 9024665. DOI: 10.3390/antibiotics11040427. View

4.
Sadouki Z, Wey E, Iype S, Nasralla D, Potts J, Spiro M . Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fiber system. Transpl Infect Dis. 2024; 27(1):e14396. PMC: 11827718. DOI: 10.1111/tid.14396. View

5.
Rawson T, Brzeska-Trafny I, Maxfield R, Almeida M, Gilchrist M, Gonzalo X . A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection. J Glob Antimicrob Resist. 2022; 29:558-562. DOI: 10.1016/j.jgar.2022.01.025. View